Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amerigen Pharmaceuticals, Inc.

http://www.amerigenpharma.com

Latest From Amerigen Pharmaceuticals, Inc.

Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway

Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.

Deals M & A

ANI Grabs 23 US Products From Amerigen

In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.

Deals United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register